Applicants: Isabelle Mansuy and Eric R. Kandel

U.S. Serial No.: 10/091,714

Filed: March 5, 2002

Page 2

Listing of Claims:

- (Currently Amended) A transgenic nonhuman mammal mouse 1. germ and somatic cells contain (i) heterologous acid nucleic sequence encoding transcriptional activator whose expression is under the control of а CaMKIIα promoter and (ii) а heterologous nucleic acid sequence encoding a calcineurin inhibitor protein whose expression is under the control of a promoter responsive to the transcriptional activator in a regulatable manner, wherein the mammal exhibits enhanced calcineurin inhibitor protein expression on induction of the transcriptional activator.
- 2. (Currently Amended) The transgenic nonhuman-mammal mouse of claim 1, wherein the transcriptional activator comprises rtTA and the promoter of the second nucleic acid sequence comprises a tetOtetracycline-responsive sequence.
- (Canceled).
- 4. (Currently Amended) The transgenic nonhuman mammal mouse of claim 1, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
- 5. (Currently Amended) The transgenic nonhuman mammal mouse of claim 1, wherein the expression of the calcineurin inhibitor protein is induced by doxycycline.
- 6. (Currently Amended) The transgenic nonhuman mammal <u>mouse</u> of claim 1, wherein the transcriptional activator comprises

Applicants: Isabelle Mansuy and Eric R. Kandel

U.S. Serial No.: 10/091,714

Filed: March 5, 2002

Page 3

tTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.

- 7. (Canceled).
- 8. (Currently Amended) The transgenic nonhuman mammal mouse of claim 6, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
- 9. (Currently Amended) The transgenic nonhuman mammal mouse of claim 6, wherein the expression of the calcineurin inhibitor protein is repressed by doxycycline.

10-20. (Canceled)

- 21. (Currently Amended) A nonhuman composition of matter comprising a nucleic acid vector comprising (i) a first nucleic acid encoding a transcriptional activator whose expression is under the control of a CaMKIIα promoter and (ii) a second nucleic acid encoding a calcineurin inhibitor protein whose expression is under the control of a promoter responsive to the transcriptional activator in a regulatable manner, wherein the nonhuman composition of matter exhibits enhanced calcineurin inhibitor protein expression on induction of the transcriptional activator.
- 22. (Canceled).
- 23. (Currently Amended) The composition of matter of claim 21, wherein the transcriptional activator comprises rtTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.

Applicants: Isabelle Mansuy and Eric R. Kandel

U.S. Serial No.: 10/091,714

Filed: March 5, 2002

Page 4

- 24. (Canceled).
- 25. (Currently Amended) The composition of matter of claim 21, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
- 26. (Currently Amended) The composition of matter of claim 21, wherein the expression of the calcineurin inhibitor protein is induced by doxycycline.
- 27. (Currently Amended) The composition of matter of claim 21, wherein the transcriptional activator comprises tTA and the promoter of the second nucleic acid sequence comprises a tetracycline-responsive sequence.
- 28. (Canceled).
- 29. (Currently Amended) The composition of matter of claim 21, wherein the calcineurin inhibitor protein comprises the carboxy-terminal autoinhibitory sequence of calcineurin.
- 30. (Currently Amended) The composition of matter of claim 21, wherein the expression of the calcineurin inhibitor protein is repressed by doxycycline.

31-34. (Canceled)